Mixed Ru(II)–Ir(III) Complexes as Photoactive Inhibitors of the Major Human Drug Metabolizing Enzyme CYP3A4
- 16 September 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 63 (40) , 18509-18518
Abstract
Cytochrome P450 3A4 (CYP3A4) is a crucial enzyme in human drug metabolism. To garner photochemical control over the inhibition of CYP3A4, a potent Ir(III)-based inhibitor of CYP3A4 was complexed with two Ru(II)-based photocaging groups. Chemical, photochemical, and biological properties of the photocaged inhibitors were characterized. Importantly, mixed Ru(II)-Ir(III) complexes strongly absorb green light, which facilitates the photochemical release of the Ir(III) inhibitor from the Ru(II) caging fragment [Ru(tpy)(Me2bpy)]2+, where tpy = 2,2':6',2″-terpyridine and Me2bpy = 6,6'-dimethyl-2,2'-bipyridine. Emission turn on, type II heme binding, and more potent inhibition under light vs dark conditions were observed. The study also demonstrated that a Ru(II)-Ir(III) conjugate can be photoactivated to exert cytotoxic effects on MCF-7 breast cancer cells upon green light exposure. Additionally, a synthesized analogue with one [Ru(TPA)]2+ fragment (TPA = tris(pyridin-2-ylmethyl)amine) and two Ir(III) centers, although resistant to photochemical release, showed strong inhibition of CYP3A4 both in purified form and in CYP3A4-overexpressing HepG2 cells, with nanomolar potency. These mixed Ru(II)-Ir(III) compounds can permeate cell membranes and inhibit CYP3A4, presenting a new class of bioactive compounds.Keywords
Funding Information
- National Institute of Environmental Health Sciences (ES025767)
- Division of Chemistry (CHE 2102508)
- Wayne State University
- National Institutes of Health (R01 GM098285-07S1, S10OD028488)
- National Institute of General Medical Sciences (T32GM142519)
This publication has 39 references indexed in Scilit:
- A Near‐Infrared Light‐Activated Photocage Based on a Ruthenium Complex for Cancer PhototherapyAngewandte Chemie, 2023
- Towards Novel Photodynamic Anticancer Agents Generating Superoxide Anion Radicals: A Cyclometalated IrIIIComplex Conjugated to a Far‐Red Emitting CoumarinAngewandte Chemie International Edition, 2019
- Ru(II) Polypyridyl Complexes Derived from Tetradentate Ancillary Ligands for Effective PhotocagingAccounts of Chemical Research, 2018
- Photoluminescence Lifetime Imaging of Synthesized Proteins in Living Cells Using an Iridium–Alkyne ProbeAngewandte Chemie International Edition, 2017
- Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicityChemico-Biological Interactions, 2016
- Luminescent Rhenium(I) and Iridium(III) Polypyridine Complexes as Biological Probes, Imaging Reagents, and Photocytotoxic AgentsAccounts of Chemical Research, 2015
- Metal complexes and time-resolved photoluminescence spectroscopy for sensing applicationsJournal of Photochemistry and Photobiology A: Chemistry, 2015
- Tracking Cancer Metastasis In Vivo by Using an Iridium‐Based Hypoxia‐Activated Optical Oxygen NanosensorAngewandte Chemie International Edition, 2015
- Inhibition of Cathepsin Activity in a Cell‐Based Assay by a Light‐Activated Ruthenium CompoundChemMedChem, 2014
- Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicologyToxicology in Vitro, 2001